Begin typing your search above and press return to search.
exit_to_app
exit_to_app
Homechevron_rightIndiachevron_rightSII's Covovax becomes...

SII's Covovax becomes first Indian Covid vax to be sold in Europe: Adar Poonawalla

text_fields
bookmark_border
SIIs Covovax becomes first Indian Covid vax to be sold in Europe: Adar Poonawalla
cancel

Serum Institute of India CEO Adar Poonawalla on Tuesday said that in a first, a vaccine made in India is being sold in Europe. He informed that they had a stockpile of 200 million doses, adding they had already exported 40 million doses to European countries and Australia.

Mr Poonawalla, in an exclusive interview with ANI, said, "We have a stockpile of 200 million doses of Covishield...We've already exported 40 million doses of Covovax to European countries, Australia. It's for the first time that a vaccine made in India is sold in Europe."

Calling it an "important milestone, Mr Poonawalla said, "We hope that in future other vaccines made in India will also be accepted and used in Europe."

Meanwhile, the Covovax has been approved by the Drugs Controller General of India (DCGI) for children above 12 years of age, but its administration has not been allowed yet.

To this, Mr Poonawalla said, "Covovax will be used for children. It has been approved by DCGI and we're waiting for the Government of India to allow us to put it on the CoWIN app to make it available to everyone."

If it's taken in the government program also, then the SII will charge the same price of ₹ 225 even for the private market, he said.

When asked about the mix-and-match trials of Covid vaccines such that Covovax is used as a booster, Mr Poonawalla said that SII has been asked to conduct a study on that.

"We will do that trial. Covovax, in about two or three months, can also be made available as a booster. But at the moment, it is approved for children of the age of 12 and above," he said.

Mr Poonawalla has also requested the Centre to reduce the gap between the second and the third dose of the Covid vaccine to six months from the existing nine.

"The (vaccine inoculation) uptick right now is a bit slow...because we have got this rule that you have to wait for nine months between dose two and three. We have appealed to the government on how to reduce this further to six months, will propose the six-month gap," he said.

Show Full Article
TAGS:Serum Institute of India Europe Adar Poonawalla 
Next Story